Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 826 results for "gilead sciences"

Gilead signs hepatitis C pact to cut drug cost for poor
Reuters

Gilead Sciences picks India to lower drug cost

Hepatitis C drug cost to dip from $30,000 to $300 a month US drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations. Asian Age, 1 hour ago
Gilead allows 7 companies to make Hepatitis C medicine Hindu Business Line, 8 hours ago
[x]  

128 images for gilead sciences

Med India, 16 hours ago
American Banking News, 4 days ago
Wall Street Pit, 3 days ago
Wall Street Pit, 3 days ago
Wall Street Pit, 3 days ago
Wall Street Pit, 3 days ago
Wall Street Pit, 3 days ago
Wall Street Pit, 3 days ago
Wall Street Pit, 3 days ago
Wall Street Pit, 3 days ago
AlertNet

Gilead mulls price of next version of Sovaldi as Oregon says it's already too high

The $84,000 price tag of Gilead Sciences hepatitis C drug is raising eyebrows in Oregon and beyond, but the Foster City company says that the next generation of the drug may not cost significantly more. Next month, the U.S. Food and Drug ...
 San Francisco Chronicle2 hours ago Gilead To Boost Price Of New Hepatitis C Drug  Kaiser Health News9 hours ago Gilead to raise price for new hepatitis C drug above $84,000  Reuters3 days ago Gilead to price new hepatitis C drug above $84,000  DNA India2 days ago
[x]  

SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 2.58% Loss

(Comtex SmarTrend(R)) Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $99.33 to a high of $102.10. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $102.89 on volume of 18.1 ...
 Individual.com4 hours ago
Business Standard

Angel Broking remains neutral on Cipla and Cadila Healthcare

According to sources, multinational American drug maker Gilead Sciences is set to join hands with at least 5 Indian generic pharmaceutical companies and allow them to manufacture and sell cheaper versions of its new hepatitis C medicines - ...
 MyIris18 hours ago Cipla at new high, eyes deal with Gilead for hepatitis drug  Money Control19 hours ago Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries  Business Standard1 day ago Gilead Sciences to Allow 5 Indian Firms to Sell Hepatitis Generics in 90 Countries  MedIndia16 hours ago
[x]  

Retrophin, Inc., Gilead Sciences, Inc., And Our Healthcare Values

Have you ever wondered how our society values innovation, how it rewards breakthrough discoveries? Most people say that it's the price we place on new drugs that shows how much we value the breakthrough. Supposedly our willingness as a society to ...
 BioSpace10 hours ago Retrophin, Gilead, And Our Healthcare Innovation Values  Forbes.com6 hours ago

Gilead Sciences (GILD) Showing Bullish Technicals With Support At $100.47

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center Aare highlighting two trades on Gilead Sciences Inc (http://www.marketintelligencecenter.com/symbol/GILD"GILD) today after it ...
 Individual.com9 hours ago Gilead Sciences (GILD) Trading Near $109.87 Resistance Level  TradingCharts.com4 days ago

Why Is Gilead Sciences, Inc. Stock Offering This Drug for Cheap?

Gilead Sciences' ( NASDAQ: GILD ) Sovaldi has been a game changing therapy for thousands of patients in America and Europe, but patients living in poverty stricken countries in Africa and Asia have been shut out from the drug, which costs $84,000 ...
 Motley Fool9 hours ago 3 Reasons Gilead Sciences, Inc.'s Stock Could Fall  Motley Fool1 week ago
Business Standard

Zydus gets Gilead licence for Hepatitis C treatment

Cadila Healthcare Ltd (Zydus Cadila) on Monday said it has been granted generic licence by Gilead Sciences Inc, to manufacture breakthrough treatment of Hepatitis C. The two companies have entered into a generic, non-exclusive licensing agreement ...
 Hindu Business Line11 hours ago Zydus granted license to produce generic hepatitis C drug  Smart Investor11 hours ago Zydus Cadila bags license for hepatitis C drug  Business Standard11 hours ago

Gilead OKs Generic Sovaldi To Expand Global Access

Posted 11:35 AM ET Big-cap biotech and IBD 50 stock Gilead Sciences (NASDAQ:GILD) said Monday that it's licensing its megablockbuster hepatitis C drug Sovaldi to seven Indian generic-drug companies to improve access in 91 developing countries.
 Investor's Business Daily9 hours ago Video: Gilead OKs Generic Sovaldi To Expand Access  Investor's Business Daily3 hours ago

7 Indian firms to make Hepatitis C drug

Comment · print · T T T+· T- TOPICS U.S. pharmaceutical major Gilead Sciences signs non-exclusive licensing agreements with these firms In a move to make the treatment for Hepatitis C more affordable in developing markets, U.S.
 The Hindu9 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less